18,667 research outputs found
Interaction-induced localization of anomalously-diffracting nonlinear waves
We study experimentally the interactions between normal solitons and tilted
beams in glass waveguide arrays. We find that as a tilted beam, traversing away
from a normally propagating soliton, coincides with the self-defocusing regime
of the array, it can be refocused and routed back into any of the intermediate
sites due to the interaction, as a function of the initial phase difference.
Numerically, distinct parameter regimes exhibiting this behavior of the
interaction are identified.Comment: Physical Review Letters, in pres
Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial
Background Moderate cooling after birth asphyxia is associated with substantial reductions in death and disability, but additional therapies might provide further benefit. We assessed whether the addition of xenon gas, a promising novel therapy, after the initiation of hypothermia for birth asphyxia would result in further improvement. Methods Total Body hypothermia plus Xenon (TOBY-Xe) was a proof-of-concept, randomised, open-label, parallel-group trial done at four intensive-care neonatal units in the UK. Eligible infants were 36–43 weeks of gestational age, had signs of moderate to severe encephalopathy and moderately or severely abnormal background activity for at least 30 min or seizures as shown by amplitude-integrated EEG (aEEG), and had one of the following: Apgar score of 5 or less 10 min after birth, continued need for resuscitation 10 min after birth, or acidosis within 1 h of birth. Participants were allocated in a 1:1 ratio by use of a secure web-based computer-generated randomisation sequence within 12 h of birth to cooling to a rectal temperature of 33·5°C for 72 h (standard treatment) or to cooling in combination with 30% inhaled xenon for 24 h started immediately after randomisation. The primary outcomes were reduction in lactate to N-acetyl aspartate ratio in the thalamus and in preserved fractional anisotropy in the posterior limb of the internal capsule, measured with magnetic resonance spectroscopy and MRI, respectively, within 15 days of birth. The investigator assessing these outcomes was masked to allocation. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00934700, and with ISRCTN, as ISRCTN08886155. Findings The study was done from Jan 31, 2012, to Sept 30, 2014. We enrolled 92 infants, 46 of whom were randomly assigned to cooling only and 46 to xenon plus cooling. 37 infants in the cooling only group and 41 in the cooling plus xenon group underwent magnetic resonance assessments and were included in the analysis of the primary outcomes. We noted no significant differences in lactate to N-acetyl aspartate ratio in the thalamus (geometric mean ratio 1·09, 95% CI 0·90 to 1·32) or fractional anisotropy (mean difference −0·01, 95% CI −0·03 to 0·02) in the posterior limb of the internal capsule between the two groups. Nine infants died in the cooling group and 11 in the xenon group. Two adverse events were reported in the xenon group: subcutaneous fat necrosis and transient desaturation during the MRI. No serious adverse events were recorded. Interpretation Administration of xenon within the delayed timeframe used in this trial is feasible and apparently safe, but is unlikely to enhance the neuroprotective effect of cooling after birth asphyxia
The Einstein-Vlasov sytem/Kinetic theory
The main purpose of this article is to guide the reader to theorems on global
properties of solutions to the Einstein-Vlasov system. This system couples
Einstein's equations to a kinetic matter model. Kinetic theory has been an
important field of research during several decades where the main focus has
been on nonrelativistic- and special relativistic physics, e.g. to model the
dynamics of neutral gases, plasmas and Newtonian self-gravitating systems. In
1990 Rendall and Rein initiated a mathematical study of the Einstein-Vlasov
system. Since then many theorems on global properties of solutions to this
system have been established. The Vlasov equation describes matter
phenomenologically and it should be stressed that most of the theorems
presented in this article are not presently known for other such matter models
(e.g. fluid models). The first part of this paper gives an introduction to
kinetic theory in non-curved spacetimes and then the Einstein-Vlasov system is
introduced. We believe that a good understanding of kinetic theory in
non-curved spacetimes is fundamental in order to get a good comprehension of
kinetic theory in general relativity.Comment: 31 pages. This article has been submitted to Living Rev. Relativity
(http://www.livingreviews.org
Coherent quantum phase slip
A hundred years after discovery of superconductivity, one fundamental
prediction of the theory, the coherent quantum phase slip (CQPS), has not been
observed. CQPS is a phenomenon exactly dual to the Josephson effect: whilst the
latter is a coherent transfer of charges between superconducting contacts, the
former is a coherent transfer of vortices or fluxes across a superconducting
wire. In contrast to previously reported observations of incoherent phase slip,
the CQPS has been only a subject of theoretical study. Its experimental
demonstration is made difficult by quasiparticle dissipation due to gapless
excitations in nanowires or in vortex cores. This difficulty might be overcome
by using certain strongly disordered superconductors in the vicinity of the
superconductor-insulator transition (SIT). Here we report the first direct
observation of the CQPS in a strongly disordered indium-oxide (InOx)
superconducting wire inserted in a loop, which is manifested by the
superposition of the quantum states with different number of fluxes. Similarly
to the Josephson effect, our observation is expected to lead to novel
applications in superconducting electronics and quantum metrology.Comment: 14 pages, 3 figure
Early Life Socioeconomic Circumstance and Late Life Brain Hyperintensities : A Population Based Cohort Study
Funding: Image acquisition and image analysis for this study was funded by the Alzheimer's Research Trust (now Alzheimer's Research UK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Acknowledgments The authors would like to thank the participants of the Aberdeen 1936 Birth Cohort (ABC36), without whom this research would not have been possible.Peer reviewedPublisher PD
Bevacizumab for newly diagnosed ovarian cancers: Best candidates among high-risk disease patients (icon-7)
Bevacizumab is approved as a maintenance treatment in first-line setting in advanced-stage III-IV ovarian cancers, because GOG-0218 and ICON-7 phase III trials demonstrated progression-free survival benefits. However, only the subgroup of patients with high-risk diseases (stage IV, and incompletely resected stage III) derived an overall survival (OS) gain in the ICON-7 trial (4.8 months). The modeled CA-125 elimination rate constant K (KELIM) parameter, based on the longitudinal CA- 125 kinetics during the first 100 days of chemotherapy, is a potential indicator of the tumor primary chemo-sensitivity. In the ICON-7 trial dataset, the OS of patients within the low- and high-risk disease groups was assessed according to treatment arms and KELIM. Among the patients with high-risk diseases, those with favorable standardized KELIM of at least 1.0 (n=214, 46.7%) had no survival benefit from bevacizumab, whereas those with unfavorable KELIM less than 1.0 (n=244, 53.2%) derived the highest OS benefit (absolute difference = 9.1 months, 2-sided log-rank P=.10; Cox hazard ratio = 0.78, 95% confidence interval = 0.58 to 1.04, 2-sided P=.09)
Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)
Bevacizumab is approved as a maintenance treatment in first-line setting in advanced-stage III-IV ovarian cancers, because GOG-0218 and ICON-7 phase III trials demonstrated progression-free survival benefits. However, only the subgroup of patients with high-risk diseases (stage IV, and incompletely resected stage III) derived an overall survival (OS) gain in the ICON-7 trial (4.8 months). The modeled CA-125 elimination rate constant K (KELIM) parameter, based on the longitudinal CA-125 kinetics during the first 100 days of chemotherapy, is a potential indicator of the tumor primary chemo-sensitivity. In the ICON-7 trial dataset, the OS of patients within the low- and high-risk disease groups was assessed according to treatment arms and KELIM. Among the patients with high-risk diseases, those with favorable standardized KELIM of at least 1.0 (n = 214, 46.7%) had no survival benefit from bevacizumab, whereas those with unfavorable KELIM less than 1.0 (n = 244, 53.2%) derived the highest OS benefit (absolute difference = 9.1 months, 2-sided log-rank P = .10; Cox hazard ratio = 0.78, 95% confidence interval = 0.58 to 1.04, 2-sided P = .09)
Alpha-particle clustering in excited expanding self-conjugate nuclei
The fragmentation of quasi-projectiles from the nuclear reaction 40Ca + 12C
at 25 MeV/nucleon was used to produce alpha-emission sources. From a careful
selection of these sources provided by a complete detection and from
comparisons with models of sequential and simultaneous decays, strong
indications in favour of -particle clustering in excited 16O, 20Ne and
24}Mg are reported.Comment: 8 pages, 4 figures, 12th International Conference on Nucleus-Nucleus
collisions (NN2015), 21-26 June 2015, Catania, Ital
CPT Violation, Strings, and Neutral-Meson Systems
This talk provides a short overview of recent results on possible CPT
violation and some associated experimental signatures.Comment: Presented at Orbis Scientiae, January 199
Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review.
BACKGROUND: Deposition of amyloid-beta (Abeta) in vessel walls of the brain as cerebral amyloid angiopathy (CAA) could be a major factor in the pathogenesis of dementia. Here we investigate the relationship between dementia and the prevalence of CAA in older populations. We searched the literature for prospective population-based epidemiological clinicopathological studies, free of the biases of other sampling techniques, which were used as a comparison. METHODS: To identify population-based studies assessing CAA and dementia, a previous systematic review of population-based clinicopathological studies of ageing and dementia was employed. To identify selected-sample studies, PsychInfo (1806-April Week 3 2008), OVID MEDLINE (1950-April Week 2 2008) and Pubmed (searched 21 April 2008) databases were searched using the term "amyloid angiopathy". These databases were also employed to search for any population-based studies not included in the previous systematic review. Studies were included if they reported the prevalence of CAA relative to a dementia classification (clinical or neuropathological). RESULTS: Four population-based studies were identified. They showed that on average 55-59% of those with dementia displayed CAA (of any severity) compared to 28-38% of the non-demented. 37-43% of the demented displayed severe CAA in contrast to 7-24% of the non-demented. There was no overlap in the range of these averages and they were less variable and lower than those reported in 38 selected sample studies (demented v non-demented: 32-100 v 0-77% regardless of severity; 0-50 v 0-11% for severe only). CONCLUSION: CAA prevalence in populations is consistently higher in the demented as compared to the non-demented. This supports a significant role for CAA in the pathogenesis of dementia
- …